Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 8 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available Also in German MOST POPULAR Coping With the Difficult Times of Cancer Survivorship Through My “Bucket... August 1, 2023 Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... February 11, 2022 A Positive Trend in OS Improvement Favours Atezolizumab Compared to Best... August 11, 2023 Targeted Drug Trio Improves Survival in Colorectal Cancer with BRAF Mutations November 13, 2019 Load more HOT NEWS Pregnant Mom Experiencing Severe Leg And Back Pain Diagnosed With Stage... NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous... The Future Front Line: Pre-Med During COVID-19 Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia Vera
